According to GlycoMimetics 's latest financial reports the company's current earnings (TTM) are -$38.07 M. In 2022 the company made an earning of -$46.69 M an increase over its 2021 earnings that were of -$63.43 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$38.07 M | -18.47% |
2022 | -$46.69 M | -26.39% |
2021 | -$63.43 M | 24.3% |
2020 | -$51.03 M | -11.86% |
2019 | -$57.9 M | 19.92% |
2018 | -$48.28 M | 56.93% |
2017 | -$30.77 M | -3.29% |
2016 | -$31.81 M | 149.11% |
2015 | -$12.77 M | 14.81% |
2014 | -$11.13 M | 4.87% |
2013 | -$10.61 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $16.97 B | -44,687.95% | ๐บ๐ธ USA |
Pfizer PFE | $3.26 B | -8,682.89% | ๐บ๐ธ USA |
Sanofi SNY | $8.39 B | -22,155.80% | ๐ซ๐ท France |
Palatin Technologies PTN | -$31.58 M | -17.04% | ๐บ๐ธ USA |
bluebird bio
BLUE | -$91.14 M | 139.43% | ๐บ๐ธ USA |